Verdence Capital Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Verdence Capital Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,651	Closed	-$503K	–	556
2023 Q1	$503K	Buy	3,651 +1	+0%	+$130	0.06%	307
2022 Q4	$473K	Hold	3,650	–	–	0.06%	290
2022 Q3	$403K	Hold	3,650	–	–	0.06%	315
2022 Q2	$274K	Hold	3,650	–	–	0.04%	411
2022 Q1	$285K	Hold	3,650	–	–	0.03%	434
2021 Q4	$329K	Sell	3,650 -140	-4%	-$12K	0.04%	387
2021 Q3	$350K	Sell	3,790 -1,610	-30%	-$124K	0.05%	345
2021 Q2	$420K	Buy	5,400 +1,400	+35%	+$106K	0.06%	283
2021 Q1	$298K	Buy	4,000 +50	+1%	+$4.61K	0.05%	358
2020 Q4	$673K	Sell	3,950 -3,500	-47%	-$519K	0.13%	167
2020 Q3	$1.05M	Buy	+7,450	New	+$1.13M	0.24%	111

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Verdence Capital Advisors's SRPT Position: Q2 2023 in Review

Verdence Capital Advisors sold out of Sarepta Therapeutics (SRPT) in Q2 2023, closing a stake of 3,651 shares — an estimated $503K sold.

Verdence Capital Advisors first reported a position in SRPT in Q3 2020 and held it in 11 quarters. The position peaked at $1.05M in Q3 2020. 404 funds tracked by Wall St. Rank hold SRPT as of Q2 2023.

Verdence Capital Advisors reported no remaining Sarepta Therapeutics position as of Q2 2023 after selling out during the quarter.
Verdence Capital Advisors sold 3,651 Sarepta Therapeutics shares in Q2 2023, an estimated $503K.
Verdence Capital Advisors first reported a position in Sarepta Therapeutics in Q3 2020 and held it in 11 quarters.
Verdence Capital Advisors's Sarepta Therapeutics position peaked at $1.05M in Q3 2020.
404 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2023.

Based on Verdence Capital Advisors's 13F filing for Q2 2023, filed 31 Jul 2023.